Pneumococcal vaccine and patients with pulmonary diseases

Mehdi Mirsaeidi, Golnaz Ebrahimi, Mary Beth Allen, Stefano Aliberti

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Chronic pulmonary diseases are chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension, and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality, especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (eg, methotrexate, anti-tumor necrosis factor inhibitors), or who have concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection/acquired immunodeficiency syndrome, nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine and the pneumococcal polysaccharide vaccine 23-valent.

Original languageEnglish (US)
Pages (from-to)886.e1-886.e8
JournalAmerican Journal of Medicine
Issue number9
StatePublished - Sep 1 2014
Externally publishedYes


  • Invasive pneumococcal disease
  • Pneumococcal
  • Pneumonia
  • Pulmonary
  • Streptococcus pneumoniae
  • Vaccination

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pneumococcal vaccine and patients with pulmonary diseases'. Together they form a unique fingerprint.

Cite this